Our mission and strategy

Our mission is to help people do more, feel better, live longer.

The business is focused around the delivery of three strategic priorities which aim to increase growth, reduce risk and improve our long-term financial performance. These priorities are: grow a diversified global business, deliver more products of value, and simplify the operating model.

 
Operating responsibly and ensuring our values are embedded in our culture and decision-making helps us better meet the expectations of society.

Grow a diversified business

Our aim

We have been creating a more balanced business and product portfolio, capable of delivering sustainable sales growth.

This is centred on our three business areas of Pharmaceuticals, Vaccines and Consumer Healthcare.

Highlights

£23bn Group turnover
40% Group turnover outside USA and Europe

Deliver more products of value

Our aim

We have changed our R&D organisation so that it is better able to sustain a pipeline of products that offer valuable improvements in treatment for patients and healthcare providers.

This is underpinned by a focus on improving productivity and rates of return in R&D.

Highlights

4 significant new product approvals in 2014
Around 40 new molecular entities in phase II and III

Simplify the operating model

Our aim

As our business continues to change shape, we are transforming how we operate so that we can reduce complexity and become more efficient.

This frees up resources to reinvest elsewhere in the business.

Highlights

33 days increase in working capital
10 working capital days improvement (adjusted)

Responsible business

Our aim

Being a responsible business is central to our strategy, and how we deliver success is just as important as what we achieve. Ensuring our values are embedded in our culture and decision-making helps us better meet the expectations of society.

Highlights

1st in 2014 Access to Medicines Index
84% Dow Jones Sustainability Index score, placing us in the top 2% of our sector